- Home
- PLYX vs ATRA Comparison
PLYX vs ATRA Comparison
Compare PLYX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLYX | ATRA |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.7M | 94.2M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PLYX | ATRA |
|---|---|---|
| Price | $1.76 | $8.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $7.50 | ★ $13.67 |
| AVG Volume (30 Days) | ★ 24.1K | 20.3K |
| Earning Date | 11-14-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 77.53 | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,334.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.76 | $3.92 |
| 52 Week High | $10.93 | $19.15 |
Technical Indicators
Market Signals| Indicator | PLYX | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 33.92 | 40.53 |
| Support Level | N/A | $7.72 |
| Resistance Level | $2.18 | $9.93 |
| Average True Range (ATR) | 0.11 | 0.57 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 13.00 | 21.26 |
Price Performance
Historical ComparisonAbout PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.